Beyond randomized controlled trials: A "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab

Pediatric Pulmonology

Volumn 41, Issue 12, 2006, Pages 1167-1174

  Mitchell, Ian ^a,d   Tough, Suzanne ^a   Gillis, Lynne ^b   Majaesic, Carina ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Decision Support Research Team   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Bronchiolitis; Chronic lung disease; Hospitalization; Palivizumab; Preterm infants; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

CANADA; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GESTATIONAL AGE; HEALTH CARE SYSTEM; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS INFECTION;

ALBERTA; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; MALE; PREVALENCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RETROSPECTIVE STUDIES; RISK FACTORS; SEASONS; TREATMENT OUTCOME;

EID: 33845457121     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20507     Document Type: Review

References (22)

1. McConnochie KM, Hall CB, Barker WH. Lower respiratory tract illness in the first two years of life: epidemiologic patterns and costs in a suburban pediatric practice. Am J Public Health 1988;78:34-39.
2. Health Canada, PPHB. Respiratory Virus Detections/Isolations in Canada, http://www.hc-sc.gc.ca/pphb-dgspsp/bid-bmi/dsd-dsm/rvdi-divr/2003pdf/rvdi1103. pdf Report Accessed 21-3-2003.
3. Statistics Canada, Statistics Canada. 2001 Census, http://www12.statean. ca/english/census01/products/standard/themes/RetrieveProductTable.cfm Report Accessed 21-3-2003.
4. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.[comment]. Pediatrics 1998;102:531-537.
5. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr., Connor EM, Sondheimer HM; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-540.
6. Committee on Infectious Diseases and Committee on Fetus and Newborn. "Prevention of Respiratory Syncytial Virus Infections: indications for the Use of Palivizumab and Update on the Use of RSV-IGIV." Pediatrics 1998;102:1211-1216.
7. Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS). Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatrics Child Health 1999;4:474-480.
8. Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS). Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants, http://www.cps.ca/english/statements/ID/id99-06.htm Accessed 15-March-2005.
9. Forster J. Prophylaxis of RSV infections with immunoglobulins. Report of the German Society of Pediatric Infectiology (DGPI). Monatsschrift Kinderheilkunde 1999;10:971-972.
10. Azar P, Broglia B, Miceli INP, Parga L, Castillo EAS, Filho NA, Costa HPF, Kopelman BI, Miranda LEV, Caravajal LFA, Weinstein SV, Hoyos A, Valencia A, Castellanos AE, Davilla JJA, Cadeño NEJ, de Sierra TM, Mora EM, Friere MJS. Guidelines for the use of palivizumab in the prevention of RSV disease: a consensus opinion. Pediatr Rev (Spanish) 2000;21:62-68.
11. Nishida H, Takeuchi Y, Fujimura M, Ogawa Y, Tsutsumi H. Prevention of severe lower respiratory tract infections due to respiratory syncytial virus in high-risk infants - Guidelines for the use of SYNAGIS® (palivizumab) in Japan. 2001.
12. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88:527-532.
13. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-219.
14. Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, Chetcuti PA, Shaw NJ, Woods A, Boorman J, Coles S, Turner J. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463-468.
15. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001;35:1186-1193.
16. Paranka M, Brown M, Thomas P, Peabody J, Clark R. Are very low birth weight infants born at high altitude at greater risk for adverse outcomes? J Pediatr 2001;139:669-672.
17. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infections. Pediatrics 2006;117:349-356.
18. Deshpande SA, Northern V The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-1069.
19. Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, Lenney W, Melville S, Shaw NJ, Boorman J, Coles S, Turner J, Pang F. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89:673-678.
20. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150-S156.
21. Simoes EAF, Carbonell-Estrany X, Kimpen J, Rieger CHL, Morris DD, Pollack PF. Palivizumab use decreases risk of recurrent wheezing in preterm children. Presentation at European Respiratory Society, Glasgow, September 05, 2004.
22. Moynihan JA, Kim TY, Young T, Checchia PA. Rate of palivizumab administration in accordance with current recommendations among hospitalized children. J Pediatr Health Care 2004;18:224-227.